Cargando…
Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report)
In this study, the use of fibrin rich in leukocytes and platelets (L-PRF) was explored to heal osteomyelitis ulcers in a diabetic foot. The goal was to standardize the utilization of L-PRF in patients with osteomyelitis to direct it for healing. L-PRF was obtained autologously from the peripheral bl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023512/ https://www.ncbi.nlm.nih.gov/pubmed/29695061 http://dx.doi.org/10.3390/diseases6020030 |
_version_ | 1783335886222524416 |
---|---|
author | Crisci, Alessandro Marotta, Giuseppe Licito, Anna Serra, Edda Benincasa, Giulio Crisci, Michela |
author_facet | Crisci, Alessandro Marotta, Giuseppe Licito, Anna Serra, Edda Benincasa, Giulio Crisci, Michela |
author_sort | Crisci, Alessandro |
collection | PubMed |
description | In this study, the use of fibrin rich in leukocytes and platelets (L-PRF) was explored to heal osteomyelitis ulcers in a diabetic foot. The goal was to standardize the utilization of L-PRF in patients with osteomyelitis to direct it for healing. L-PRF was obtained autologously from the peripheral blood of the diabetic patients (n = 3) having osteomyelitis and skin lesions for at least six months. The L-PRF and supernatant serum were inserted into the skin lesion to the bone after a surgical debridement. The evolution of lesions over time was analyzed. All three patients showed positivity to the Probe-to-Bone test and Nuclear Magnetic Resonance detected cortico-periosteal thickening and/or outbreaks of spongy cortical osteolysis in adjacency of the ulcer. The infections were caused by Cocci Gram-positive bacteria, such as S. Aureus, S. β-hemolytic, S. Viridans and Bacilli; and Gram-negative such as Pseudomonas, Proteus, Enterobacter; and yeast, Candida. The blood count did not show any significant alterations. To date, all three patients have healed skin lesions (in a patient for about two years) with no evidence of infection. These preliminary results showed that L-PRF membranes could be a new method of therapy in such problematic diseases. Overall, the L-PRF treatment in osteomyelitis of a diabetic foot seems to be easy and cost-effective by regenerative therapy of chronic skin lesions. In addition, it will improve our understanding of wound healing. |
format | Online Article Text |
id | pubmed-6023512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60235122018-07-03 Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report) Crisci, Alessandro Marotta, Giuseppe Licito, Anna Serra, Edda Benincasa, Giulio Crisci, Michela Diseases Case Report In this study, the use of fibrin rich in leukocytes and platelets (L-PRF) was explored to heal osteomyelitis ulcers in a diabetic foot. The goal was to standardize the utilization of L-PRF in patients with osteomyelitis to direct it for healing. L-PRF was obtained autologously from the peripheral blood of the diabetic patients (n = 3) having osteomyelitis and skin lesions for at least six months. The L-PRF and supernatant serum were inserted into the skin lesion to the bone after a surgical debridement. The evolution of lesions over time was analyzed. All three patients showed positivity to the Probe-to-Bone test and Nuclear Magnetic Resonance detected cortico-periosteal thickening and/or outbreaks of spongy cortical osteolysis in adjacency of the ulcer. The infections were caused by Cocci Gram-positive bacteria, such as S. Aureus, S. β-hemolytic, S. Viridans and Bacilli; and Gram-negative such as Pseudomonas, Proteus, Enterobacter; and yeast, Candida. The blood count did not show any significant alterations. To date, all three patients have healed skin lesions (in a patient for about two years) with no evidence of infection. These preliminary results showed that L-PRF membranes could be a new method of therapy in such problematic diseases. Overall, the L-PRF treatment in osteomyelitis of a diabetic foot seems to be easy and cost-effective by regenerative therapy of chronic skin lesions. In addition, it will improve our understanding of wound healing. MDPI 2018-04-24 /pmc/articles/PMC6023512/ /pubmed/29695061 http://dx.doi.org/10.3390/diseases6020030 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Crisci, Alessandro Marotta, Giuseppe Licito, Anna Serra, Edda Benincasa, Giulio Crisci, Michela Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report) |
title | Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report) |
title_full | Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report) |
title_fullStr | Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report) |
title_full_unstemmed | Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report) |
title_short | Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report) |
title_sort | use of leukocyte platelet (l-prf) rich fibrin in diabetic foot ulcer with osteomyelitis (three clinical cases report) |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023512/ https://www.ncbi.nlm.nih.gov/pubmed/29695061 http://dx.doi.org/10.3390/diseases6020030 |
work_keys_str_mv | AT criscialessandro useofleukocyteplateletlprfrichfibrinindiabeticfootulcerwithosteomyelitisthreeclinicalcasesreport AT marottagiuseppe useofleukocyteplateletlprfrichfibrinindiabeticfootulcerwithosteomyelitisthreeclinicalcasesreport AT licitoanna useofleukocyteplateletlprfrichfibrinindiabeticfootulcerwithosteomyelitisthreeclinicalcasesreport AT serraedda useofleukocyteplateletlprfrichfibrinindiabeticfootulcerwithosteomyelitisthreeclinicalcasesreport AT benincasagiulio useofleukocyteplateletlprfrichfibrinindiabeticfootulcerwithosteomyelitisthreeclinicalcasesreport AT criscimichela useofleukocyteplateletlprfrichfibrinindiabeticfootulcerwithosteomyelitisthreeclinicalcasesreport |